1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Legislation

US FDA's Consumer Health Oversight Absent From Appropriators’ Request For COVID-19 Assessment

At 90 And Counting, Will Supplement Warnings Merit Mention In Response?

 
• By Malcolm Spicer

House appropriators don’t mention the consumer health market in requesting a report on FDA’s response to COVID-19, but the agency’s frequent warnings about products marketed with unlawful claims could merit mentioning. Encouraging accelerated production of hand sanitizers while also ensuring the additional supplies are safe is another component of its COVID-19 response that could be covered in an assessment of its response to the pandemic.

Test result of a Corona test. Hand turns a dice and changes the expression "positive COVID19" to "negative COVID19".

US House appropriators don’t mention the consumer health market in requesting a report on the Food and Drug Administration’s response to the COVID-19 pandemic, but the agency’s frequent warnings about products marketed with unlawful claims could merit mentioning in its report.

Encouraging accelerated product of hand sanitizers while also ensuring the additional supplies are safe is another component of its COVID-19...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.

Paying User Fees Not A Priority For Many OTC Monograph Drug Firms, First Arrears List Shows

 
• By Malcolm Spicer

The 1,383 entries on OMUFA arrears list for facility registrations from FY2021 through FY2025 on FDA’s list exceeds its estimate of 1,134 entities subject to the fee for FY2025.